Anti-hVISTA-hIgG1NQ
-
Cat.code:
hvista-mab12
- Documents
ABOUT
Anti-human VISTA - Human non-glycosylated IgG1 (low effector functions)
Anti-hVISTA-hIgG1NQ is a Onvatilimab-based research antibody with a non-glycosylated human IgG1. Onvatilimab (JNJ-61610588) is a fully human IgG1 monoclonal antibody targeting the human V-domain Ig-containing suppressor of T-cell activation (VISTA). It inhibits the engagement of VISTA with its receptor on T cells, preventing VISTA from providing negative signaling. Onvatilimab is under the investigation for the treatment of specific types of advanced solid tumors, including lung, pancreas, or colorectal cancer.
Anti-hVISTA-hIgG1NQ comprises the variable region of Onvatilimab and a non-glycosylated IgG1 constant region mediating low effector functions. For applications requiring high Fc effector activity, InvivoGen also offers Anti-hVISTA-hIgG1, a biosimilar research antibody to Onvatilimab.
This antibody can be used together with Raji-hVISTA cells for ADCC Fc effector function studies (see figure) as well as for antagonist assay to disrupt the inhibitory interaction between VISTA and its receptor/ligand.
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
Potential asparagine (N) glycosylation sites are substituted by glutamine (Q) residues, resulting in the production of a non-glycosylated antibody. Glycosylation of an antibody has no effect on antigen binding but is essential for Fc receptor-mediated activity, and therefore, the effector function of Anti‑hVISTA‑hIgG1NQ is severely compromised.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
VISTA
Human
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Flow cytometry
Each lot is functionally tested by flow cytometry.
CONTENTS
Contents
-
Product:Anti-hVISTA-hIgG1NQ
-
Cat code:hvista-mab12
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
VISTA background
V-domain Ig-containing suppressor of T-cell activation (VISTA), also known as programmed death-1 homolog (PH-1H), is a known immune checkpoint, that directly suppresses T cell activation, proliferation, and cytokine production [1]. VISTA can be considered both a ligand and a receptor, whereby it transmits inhibitory signals to T cells, either extrinsically, through expression on myeloid cells (i.e., macrophage and dendritic cells) and binding to an unknown receptor on T cells, or intrinsically, through its expression on T cells (i.e., CD4+, CD8+) [2]. In the context of cancer immunotherapy, VISTA has been found to be heightened on cells that infiltrate the tumor microenvironment (TME) and not the tumor cells themselves; therefore, VISTA-blocking antibodies are of interest. These function to inhibit the engagement of VISTA with its receptor on T cells or by directly targeting VISTA expressed on naïve and effector T cells, preventing it from providing negative signaling [1, 2].
References:
1. Nowak, E.C. et al. 2017. Immunoregulatory functions of VISTA. Immunol Rev 276, 66-79.
2. Xu, W. et al. 2018. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol 15, 438-446.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz